Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-11
Closed -$30K 6268
2015
Q4
$30K Sell
11
-6
-35% -$30.8K ﹤0.01% 5042
2015
Q3
$47K Buy
17
+9
+113% +$53.7K ﹤0.01% 5039
2015
Q2
$43K Buy
8
+3
+60% +$21.3K ﹤0.01% 5250
2015
Q1
$26K Sell
5
-12
-71% -$83.5K ﹤0.01% 5686
2014
Q4
$92K Sell
17
-1
-6% -$6.94K ﹤0.01% 5274
2014
Q3
$101K Buy
18
+2
+13% +$17.4K ﹤0.01% 5316
2014
Q2
$129K Buy
16
+4
+33% +$35.7K ﹤0.01% 5219
2014
Q1
$98K Sell
12
-30
-71% -$312K ﹤0.01% 5474
2013
Q4
$343K Hold
42
﹤0.01% 4455
2013
Q3
$522K Sell
42
-1
-2% -$14.8K ﹤0.01% 4064
2013
Q2
$541K Buy
+43
New +$598K ﹤0.01% 4114

Other funds holding IMNN

Barclays's IMNN Position: Q4 2021 in Review

Barclays sold out of Imunon (IMNN) in Q4 2021, closing a stake of 132 shares — an estimated $24K sold.

Barclays first reported a position in IMNN in Q2 2013 and held it in 13 quarters. The position peaked at $59K in Q2 2014. 37 funds tracked by Wall St. Rank hold IMNN as of Q4 2021.

  • Barclays reported no remaining Imunon position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 132 Imunon shares in Q4 2021, an estimated $24K.
  • Barclays first reported a position in Imunon in Q2 2013 and held it in 13 quarters.
  • Barclays's Imunon position peaked at $59K in Q2 2014.
  • 37 funds tracked by Wall St. Rank held Imunon as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.